The Bull Case For Disc Medicine (IRON) Could Change Following FDA Review Delay And New HR Chief Appointment
- Disc Medicine recently faced a two-week postponement of the U.S. FDA’s review of its rare disease candidate bitopertin, as regulators raised questions about efficacy endpoints, data integrity, and potential abuse risk.
- At the same time, the company appointed industry veteran Lisa Amaya Price as Chief Human Resources Officer, signaling an effort to strengthen its organizational backbone as it prepares for possible commercialization.
- Next, we’ll examine how the FDA’s temporary review delay for bitopertin shapes Disc Medicine’s investment narrative and longer-term risk profile.
Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of…
